Clinical Trial Update: Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial examined a combination of sorafenib and topotecan for platinum-resistant recurrent ovarian cancer in Phase 1/2. The study was terminated and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Sorafenib (Nexavar) (Sorafenib)
• Topotecan (Hycamtin) (Topotecan)

Snippet

Sponsor: Daniela Matei, MD | Conditions: Ovarian Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-03-03